Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 17;15(7):2024-2032.
doi: 10.7150/jca.92624. eCollection 2024.

Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study

Qiang Cao  1   2   3 , Jinyi Zhu  4 , Xinyan Wu  3   5 , Jiapeng Li  6 , Yuquan Chen  7 , Yanwei You  8 , Xiaochen Li  3   9 , Xufeng Huang  10 , Yujie Zhang  11 , Rizhu Li  12 , Dan Han  1
Affiliations

Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study

Qiang Cao et al. J Cancer. .

Abstract

Objective: This study evaluated the efficacy and safety of the gemcitabine and oxaliplatin intrathoracic perfusion chemotherapy (IPCGOR) regimen combined with interleukin-2 (IL-2) for advanced non-small cell lung cancer (NSCLC). Methods: We conducted a retrospective analysis of 460 advanced NSCLC patients from the Yunnan Province Early Cancer Diagnosis and Treatment Project (June 2020-October 2022), assessing the IPCGOR and IL-2 combination. Outcomes were measured based on RECIST 1.1 criteria, focusing on objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (MOS), and treatment safety. Results: The treatment demonstrated an ORR of 67.4%, a DCR of 97.4%, an mPFS of 8.5 months, and an MOS of 12.5 months. 14 patients underwent successful surgery post-treatment. Common adverse reactions were manageable, with no treatment-related deaths reported. Conclusion: The IPCGOR combined with IL-2 regimen shows promising efficacy and a tolerable safety profile for advanced NSCLC. These findings suggest its potential as a reference for treating advanced NSCLC. However, the study's retrospective nature and single-center design pose limitations. Future research should focus on prospective studies, randomized controlled trials, and long-term outcome assessments, particularly in diverse patient subgroups, to further validate and refine the clinical application of this regimen.

Keywords: Advanced Non-Small Cell Lung Cancer; Efficacy and Safety Evaluation; Interleukin-2 Treatment; Intrathoracic Perfusion Chemotherapy; Retrospective Cohort Study; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

References

    1. DS S, Ravindranath M. A Study of Clinical, Radiological, Histopathological Profile of Pulmonory Malignancy Cases. European Journal of Cardiovascular Medicine. 2023. 13(2)
    1. Domagala-Kulawik J, Trojnar A. Lung cancer in women in 21th century. Journal of Thoracic Disease. 2020;12(8):4398. - PMC - PubMed
    1. Zomawia E, Zami Z, Vanlallawma A. Cancer awareness, diagnosis and treatment needs in Mizoram, India: evidence from 18 years trends (2003-2020) The Lancet Regional Health-Southeast Asia. 2023. 17. - PMC - PubMed
    1. Kerpel-Fronius A, Tammemägi M, Cavic M. Screening for lung cancer in individuals who never smoked: an international association for the study of lung cancer early detection and screening committee report. Journal of Thoracic Oncology. 2022;17(1):56–66. - PubMed
    1. Yang S, Kim O J, Shin M. Association between long-term exposure to high levels of ambient air pollution and incidence of lung cancer in a population-based cohort. Environmental Research. 2021;198:111214. - PubMed